

# ZOSTAVAX<sup>®</sup> Supply/Demand Update

Eddy A. Bresnitz, MD, MSCE  
Executive Director, Adult Vaccines  
Global Vaccine Medical Affairs and Policy

Presentation to ACIP  
October 23, 2013

# Varicella Vaccine Supply Status

Merck has resumed routine supply of all varicella-based vaccines in the US while expanding the global availability for VARIVAX<sup>®</sup> and ZOSTAVAX<sup>®</sup>

- Merck returned ZOSTAVAX to normal shipping in the U.S. at end of 2011 and has shipped more than 6 million doses since then
- Re-introduced ProQuad<sup>®</sup> in the US in 2012 and have maintained uninterrupted supply of both ProQuad and VARIVAX
- ZOSTAVAX is now available in over a dozen countries, with 10+ more launches planned in 2014

# ZOSTAVAX® Supply status

Our commitment to expanding access and supply of ZOSTAVAX remains strong

- We have invested over \$1 billion in new manufacturing capabilities
  - to increase capacity
  - improve reliability, and
  - create redundancy to better ensure long-term supply
- Received FDA approval of Durham plant for varicella bulk production on September 4

